Abstract
Background
The association between HRQL measures with outcomes in patients with metastatic hormone-refractory prostate cancer (HRPC) is unclear.
Methods
Baseline and 12-week HRQL was collected using the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy – Prostate (FACT-P). Outcomes included: (1) survival; (2) time to disease progression and (3) time to bone pain. Cox proportional hazards regression models were used. The relative predictive performance of each HRQL instrument and domain was compared.
Results
Baseline HRQL scores and 12-week change scores > the median were significant predictors of all clinical outcomes but varied by domain. For example, the hazard of death for a change in FACT-P Grand Total Score > median was 49% of the hazard for a change ≤ the median. Including baseline or 12-week change in HRQL resulted in improvement in prediction performance.
Conclusions
Patients with better baseline HRQL have better predicted survival, time to disease progression and pain prognosis than those with worse HRQL. In addition, the 12-week change in HRQL appears to improve predictive accuracy for most clinical outcomes. It appears that greater deterioration in HRQL is prognostic for rapid disease progression.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Cancer Society. Available at: http://www.cancer.org/downloads/stt/Leading_Sites_of_New_Cancer_Cases_and_Deaths___2005_Estimates.pdf. Accessed December 24, 2005
Canadian Cancer Society. Available at: http://www.bc.cancer.ca/ccs/internet/standard/ 0,3182,3172_14279_langId-en,00.html. Accessed December 24, 2005
Boyle P, Ferlay J. (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16(3):481–488
U.K. National Statistics. Available at: http://www.statistics.gov.uk/statbase/Product.asp?vlnk = 14209. Accessed December 24, 2005
Australian Institute of Health and Welfare. Available at: http://www.aihw.gov.au/publications/can/ca01/ca01-c03.pdf. Accessed December 24, 2005
Petrylak DP, Tangen CM, Hussain MH, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520
Tannock IF, de Wit R, Berry WR, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
Sommers SD, Ramsey SD (1999) A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics. 16(2):127–140
Schellhammer P, Cockett A, Boccon-Gibod L, et al. (1997) Assessment of endpoints for clinical trials for localized prostate cancer. Urology 49(4A Suppl):27–38
Dancey J, Zee B, Osoba D, et al. (1997) Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. Quality of Life Research 6(2):151–158
Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M (2004) Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 101(5):1090–1098
Coates A, Porzsolt F, Osoba D. (1997) Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 33(7):1025–1030
Loprinzi CL, Laurie JA, Wieand HS, et al. (1994) Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol 12(3):601–607
Sloan JA, Loprinzi CL, Laurine JA, et al. (2001) A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol 19(15):3539–3546
Shadbolt B, Barresi J, Craft P. (2002) Self-rated health as a predictor of survival among patients with advanced cancer. J Clin Oncol 20(10):2514–2519
Coates A, Gebski V, Signorini D, et al. (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast-cancer. J Clin Oncol 10(12):1833–1838
Butow PN, Coates AS, Dunn SM (2000) Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol 11(4):469–474
Shimozuma K, Sonoo H, Ichihara K, Tanaka K (2000) The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 30(3):255–261
Coates AS, Hurny C, Peterson HF, et al. (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 18(22):3768–3774
Earlam S, Glover C, Fordy C, Burke D, AllenMersh TG (1996) Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 14(1):171–175
Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49(2):227–230
Coates A, Thomson D, McLeod GRM, et al. (1993) Prognostic value of quality-of-life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant-melanoma. Eur J Cancer 29A(12):1731–1734
Butow PN, Coates AS, Dunn SM (1999) Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 17(7):2256–2263
Buccheri GF, Ferrigno D, Tamburini M, Brunelli C (1995) The patients perception of his own quality-of-life might have an adjunctive prognostic-significance in lung-cancer. Lung Cancer Mar 12(1–2):45–58
Herndon JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J (1999) Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 85(2):333–340
Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients – as an important prognostic factor. Lung Cancer 31(2–3):233–240
Halabi S, Small EJ, Kantoff PW, et al. (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21(7):1232–1237
Cho D, Di Blasio CJ, Rhee AC, Kattan MW (2003) Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol. 21(4):282–291
Collette L, van Andel G, Bottomley A, et al. (2004) Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol. 22(19):3877–3885
Curran D, Fossa S, Aaronson N, Kiebert G, Keuppens E, Hall R (1997) Baseline quality of life of patients with advanced prostate cancer. Eur J Cancer 33(11):1809–1814
Tannock IF, Osoba D, Stockler MR, et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756–1764
Moore MJ, Osoba D, Murphy K, et al. (1994) Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 12(4):689–694
Herr HW, Kornblith AB, Ofman U (1993) A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71(3 Suppl):1143–1150
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ (1997) Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50(6):920–928
Yount S, Cella D, Banik D, Ashraf T, Shevrin D (2003) Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes 1(1):69
Harrell FE, Jr., Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15(4):361–387
Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol. 1(11):710–719
Tamburini M, Brunelli C, Rosso S, Ventafridda V (1996) Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 11(1):32–41
Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 160(6):861–868
Vigano A, Dorgan M, Buckingham J, Bruera E, Suarez-Almazor ME (2000) Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med. 14(5):363–374
Acknowledgements
This research was funded by Abbott Laboratories.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sullivan, P.W., Nelson, J.B., Mulani, P.M. et al. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res 15, 1297–1306 (2006). https://doi.org/10.1007/s11136-006-0003-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-006-0003-2